- Home
- PRAX vs NRDS Comparison
PRAX vs NRDS Comparison
Compare PRAX & NRDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- NRDS
- Stock Information
- Founded
- PRAX 2015
- NRDS 2009
- Country
- PRAX United States
- NRDS United States
- Employees
- PRAX N/A
- NRDS N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- NRDS EDP Services
- Sector
- PRAX Health Care
- NRDS Technology
- Exchange
- PRAX Nasdaq
- NRDS Nasdaq
- Market Cap
- PRAX 599.7M
- NRDS 810.0M
- IPO Year
- PRAX 2020
- NRDS 2021
- Fundamental
- Price
- PRAX $46.32
- NRDS $11.35
- Analyst Decision
- PRAX Strong Buy
- NRDS Buy
- Analyst Count
- PRAX 11
- NRDS 6
- Target Price
- PRAX $114.73
- NRDS $15.17
- AVG Volume (30 Days)
- PRAX 299.7K
- NRDS 447.0K
- Earning Date
- PRAX 08-12-2025
- NRDS 07-30-2025
- Dividend Yield
- PRAX N/A
- NRDS N/A
- EPS Growth
- PRAX N/A
- NRDS N/A
- EPS
- PRAX N/A
- NRDS 0.38
- Revenue
- PRAX $8,122,000.00
- NRDS $734,900,000.00
- Revenue This Year
- PRAX N/A
- NRDS $18.07
- Revenue Next Year
- PRAX $6,358.50
- NRDS $8.22
- P/E Ratio
- PRAX N/A
- NRDS $30.06
- Revenue Growth
- PRAX 270.02
- NRDS 24.20
- 52 Week Low
- PRAX $26.70
- NRDS $7.55
- 52 Week High
- PRAX $91.83
- NRDS $16.45
- Technical
- Relative Strength Index (RSI)
- PRAX 63.87
- NRDS 62.71
- Support Level
- PRAX $40.93
- NRDS $10.75
- Resistance Level
- PRAX $44.40
- NRDS $11.14
- Average True Range (ATR)
- PRAX 2.26
- NRDS 0.34
- MACD
- PRAX -0.08
- NRDS 0.01
- Stochastic Oscillator
- PRAX 95.12
- NRDS 96.77
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.